secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255157
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved
--------------------------------------------------------------------------------

- Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).
- Cash $310.9M at Sep 30, 2024; plus ~$28M net proceeds from greenshoe; runway into 2027.
- First-ever RNA editing in humans: WVE-006 in RestorAATion-2 showed mean M-AAT 6.9 µM at day 15 (60%+ of total AAT).
- WVE-007 (INHBE GalNAc-siRNA) obesity clinical trial on track for 1Q 2025; preclinical data supports monotherapy and GLP-1 synergy.
- WVE-003 HD: FDA open to caudate atrophy endpoint for accelerated approval; IND submission expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524255157/0001193125-24-255157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524255157/d853532d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer